Add to ORKGBACKGROUND/AIM: To assess preoperative blood levels of a biomarker panel in relation to the new classification system of epithelial ovarian cancer (EOC) type I and II.PATIENTS AND METHODS: Preoperative plasma levels of B7-family protein homolog 4 (B7-H4), intact and cleaved soluble urokinase plasminogen activator receptor (suPAR), human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) were analyzed in 350 patients with adnexal lesions.RESULTS: The levels of suPAR(II-III), HE4, CA125 were all higher in EOC II than in EOC I, borderline and benign ovarian tumors. B7-H4 was increased in EOC II compared with benign ovarian tumors. The combination of suPAR(II-III), HE4, CA125 and age in premenopausal women discriminates EOC and borderlin...
Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
ObjectiveSurvival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in la...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...
BACKGROUND/AIM: To assess preoperative blood levels of a biomarker panel in relation to the new clas...
Ovarian cancer, the most lethal of all gynecological malignancies, represents a significant public h...
Introduction Management of a woman with a pelvic mass is complicated by difficulty in discriminating...
Objective Survival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in l...
PURPOSE: To evaluate the plasma level of different forms of soluble urokinase plasminogen activator ...
Ovarian cancer is the fifth leading cause of cancer death in women in the U.S. Currently, two serum ...
Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The 5-year surviv...
Objective: Evaluating the presence of possible malignant disease in women with ovarian masses relies...
Epithelial ovarian cancer is a significant cause of mortality both in the United States and worldwid...
Objective: To evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4...
The overall mortality of ovarian cancer exceeds that of other gynecologic cancers owing to lack of d...
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
ObjectiveSurvival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in la...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...
BACKGROUND/AIM: To assess preoperative blood levels of a biomarker panel in relation to the new clas...
Ovarian cancer, the most lethal of all gynecological malignancies, represents a significant public h...
Introduction Management of a woman with a pelvic mass is complicated by difficulty in discriminating...
Objective Survival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in l...
PURPOSE: To evaluate the plasma level of different forms of soluble urokinase plasminogen activator ...
Ovarian cancer is the fifth leading cause of cancer death in women in the U.S. Currently, two serum ...
Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The 5-year surviv...
Objective: Evaluating the presence of possible malignant disease in women with ovarian masses relies...
Epithelial ovarian cancer is a significant cause of mortality both in the United States and worldwid...
Objective: To evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4...
The overall mortality of ovarian cancer exceeds that of other gynecologic cancers owing to lack of d...
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
Background: CA125 is the best available yet insufficiently sensitive biomarker for early detection o...
ObjectiveSurvival in epithelial ovarian cancer (EOC) remains poor. Most patients are diagnosed in la...
BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secre...